Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 3/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218557 | 0.91 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL3222951 | 0.91 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL3206387 | 0.91 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8988206 | 0.87 | CHRNA7 (0.52) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL9707154 | 0.85 | CHRNA7 (0.50) | CHRNA7CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8988338 | 0.83 | CHRNA7 (0.49) | CHRNA7CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8988244 | 0.83 | CHRNA7 (0.49) | CHRNA7CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8988561 | 0.83 | NAAA (0.56) | CHRNA7NAAA | |
| SCHEMBL3210416 | 0.82 | GLA (0.54) | CHRNA7CARM1PRMT6CHRM2CHRM1 | |
| SCHEMBL3219324 | 0.82 | MEN1 (0.51) | CHRNA7NAAACARM1PRMT6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | claimed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | claimed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | claimed |
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | disclosed |
| EP-1905771-A2 | Quinuclidine derivatives and their use | NeuroSearch A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | ACHE, CHRNA5, CHRNA3 | CHRNA7 9/4885NAAA 297/4885CARM1 3567/4885 |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | ACHE, CHRNA5, CHRNA3 | CHRNA7 9/4885NAAA 297/4885CARM1 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.